Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Division of Infectious Diseases and International Medicine, University of Minnesota, USA Department of Research, Minneapolis, Minnesota, United States of America.
PLoS One. 2020 Nov 9;15(11):e0241786. doi: 10.1371/journal.pone.0241786. eCollection 2020.
Latent Tuberculosis Infection (LTBI) remains a major driver of the TB epidemic, and individuals with Human Immuno-deficiency Virus (HIV) are particularly at a heightened risk of developing LTBI. However, LTBI screening among HIV-infected individuals in resource limited setting is largely based on a negative symptom screen, which has low specificity.
In a cross sectional diagnostic study, 115 HIV infected participants with a negative symptom screen will be consented and enrolled. They will be requested to donate 5 ml of blood for complete blood count (CBC) and interferon gamma release assay (IGRA) testing. In a nested prospective study, the 115 participants will be initiated on Tuberculosis Preventive Therapy and the CBC testing repeated after 3 months. In the analysis of study finding, the monocyte to lymphocyte ratio (MLR) will be derived from the dividend of the absolute monocyte and lymphocyte counts. The optimal MLR positivity cut-off for elevated or normal MLR will be the highest value of Youden's index, J (sensitivity + specificity-1). The MLR will be cross tabulated with the IGRA status to determine the sensitivity, specificity, negative and positive predictive values of the MLR. The area under the receiver operating characteristic (ROC) curve will be determined to give the overall diagnostic accuracy of MLR. The baseline and 3 month CBC will be used to determine the change in MLR, and a random effect logistic regression will be used to determine factors associated with the change in the MLR.
If positive results are realized from this study, the MLR could become an inexpensive alternative biomarker with potential to improve the specificity of the negative symptom screen in identifying individuals that should be targeted for TB preventive therapy.
潜伏性结核感染(LTBI)仍然是结核病流行的主要驱动因素,而人类免疫缺陷病毒(HIV)感染者尤其面临 LTBI 发展的高风险。然而,资源有限环境中 HIV 感染者的 LTBI 筛查主要基于阴性症状筛查,其特异性较低。
在一项横断面诊断研究中,将对 115 名有阴性症状筛查的 HIV 感染者进行同意和入组。他们将被要求捐献 5 毫升血液进行全血细胞计数(CBC)和干扰素释放试验(IGRA)检测。在一项嵌套前瞻性研究中,115 名参与者将开始接受结核病预防治疗,并在 3 个月后重复 CBC 检测。在分析研究结果时,单核细胞与淋巴细胞比值(MLR)将通过绝对单核细胞和淋巴细胞计数的商数得出。用于表示 MLR 升高或正常的最佳 MLR 阳性截断值为 Youden 指数(J)的最高值,即(灵敏度+特异性-1)。MLR 将与 IGRA 状态进行交叉制表,以确定 MLR 的敏感性、特异性、阴性预测值和阳性预测值。将确定受试者工作特征(ROC)曲线下的面积,以给出 MLR 的总体诊断准确性。将使用基线和 3 个月的 CBC 来确定 MLR 的变化,并使用随机效应逻辑回归来确定与 MLR 变化相关的因素。
如果本研究取得阳性结果,MLR 可能成为一种具有成本效益的替代生物标志物,具有提高阴性症状筛查识别需要进行结核病预防治疗的个体的特异性的潜力。